BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36112193)

  • 1. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
    Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
    Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
    Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
    Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma.
    Zhou C; Lu X; Wang Y; Qian X; Yang C; Zeng M
    Eur Radiol; 2022 Oct; 32(10):6702-6711. PubMed ID: 35976399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
    Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
    Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
    Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
    J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
    Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
    Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma.
    Zhang J; Dong W; Liu W; Fu J; Liao T; Li Y; Huo L; Jia N
    Abdom Radiol (NY); 2024 Mar; 49(3):710-721. PubMed ID: 38112787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Component prediction in combined hepatocellular carcinoma-cholangiocarcinoma: habitat imaging and its biologic underpinnings.
    Xiao Y; Huang P; Zhang Y; Lu X; Zhou C; Wu F; Wang Y; Zeng M; Yang C
    Abdom Radiol (NY); 2024 Apr; 49(4):1063-1073. PubMed ID: 38315194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
    Gigante E; Ronot M; Bertin C; Ciolina M; Bouattour M; Dondero F; Cauchy F; Soubrane O; Vilgrain V; Paradis V
    Liver Int; 2019 Dec; 39(12):2386-2396. PubMed ID: 31544304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on preoperative contrast-enhanced CT and clinical data.
    Zhang J; Dong W; Li Y; Fu J; Jia N
    Eur J Radiol; 2023 Jun; 163():110839. PubMed ID: 37121101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021).
    Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K
    J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
    Zhou C; Wang Y; Ma L; Qian X; Yang C; Zeng M
    Eur Radiol; 2022 Jan; 32(1):78-88. PubMed ID: 34279688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.